Novartis buys Myricx Bio for $1.1B in antibody drug conjugates

Novartis is dropping $1.1 billion upfront to acquire Myricx Bio, a company specializing in antibody-drug conjugates (ADCs). This move signals Novartis's deeper commitment to this targeted therapy approach, combining antibodies with potent chemotherapy agents to deliver drugs directly to cancer cells.